by Meriem Bouslouk-Marx | 10 Jul 2025
Access to gene therapies has changed the healthcare landscape. Gene therapies are a field of study for researchers and, at the same time, a never-ending complaint for healthcare payers. For patients, they bring hope and maybe a positive change in life or, above all,... 
by Meriem Bouslouk-Marx | 15 Apr 2025
Rare Diseases Worldwide This year, People Living With a Rare Disease (PLWRD) have a chance to get the recognition they deserve in Global Health. To clarify, a rare disease is a medical condition that affects fewer than or equal to 1 in 2,000 persons living in any... 
by Meriem Bouslouk-Marx | 27 May 2024
Obstacles for patient access to medicines can happen at different stages of a medicine’s life cycle. Therefore, marketing authorisation should not be the ultimate goal. Patient, regulatory and HTA perspectives on an EU approved orphan drug were discussed at the... 
by Meriem Bouslouk-Marx | 6 Oct 2023
The global community of market access professionals met in France on 2 October 2023 at the Market Access Day – the first post-pandemic event of the Market Access Society (MAS). This meeting was also a great opportunity to discuss the latest developments of the benefit... 
by Meriem Bouslouk-Marx | 7 Sep 2023
After Boehringer Ingelheim’s announcement to withdraw a medicine for the treatment of a rare skin disease from the German market on 29 August 2023, a heated debate has erupted on the benefit assessment of new therapies in Germany. Boehringer Ingelheim said the health... 
by Meriem Bouslouk-Marx | 17 Apr 2023
Do you know IMAS? IMAS stands for International Market Access Society. As a matter of fact it derives from MAS, the Market Access Society founded in France more than 10 years ago. The very first meeting of IMAS called ACCESS 2023 Miami Beach took place in April 2023....